Drug Profile
Research programme: adenosine A3 antagonists - Future Medicine
Alternative Names: A3AR antagonists - Future MedicineLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Future Medicine
- Class Antiasthmatics; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Nucleosides; Small molecules
- Mechanism of Action Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma; Middle East respiratory syndrome coronavirus; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal failure; Zika virus infection
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Asthma in South Korea
- 28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in South Korea
- 28 Apr 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea